Ephedrine Sulfate
Daten werden ergänzt – meist innerhalb einer Minute fertig
Grundinformationen
- CAS
134-72-5- Standard-SMILES
CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O- InChIKey
CAVQBDOACNULDN-KHFUBBAMSA-N- Summenformel
- C20H32N2O6S
- Durchschnittliche Molmasse
- 428,5 g/mol
- Monoisotopische Masse
- 428,19810774
Überblick
Ephedrine sulfate is a white microcrystalline powder. Odorless. Central nervous system stimulant.
Namen und Bezeichner
- Bevorzugter Name
- Ephedrine Sulfate
- IUPAC
- bis((1R,2S)-2-(methylamino)-1-phenylpropan-1-ol);sulfuric acid
Namen und Synonyme
Weitere Namen anzeigen
Datenbank-Bezeichner
- CAS
134-72-5- PubChem CID
- 5359318
- DTXSID
DTXSID6020565- ChEMBL
CHEMBL1523964- UNII
- U6X61U5ZEG
- EC Number
- 205-154-4
Eigenschaften
Berechnete StruktureigenschaftenWird ergänzt
- Polarare Oberfläche (TPSA)
- 148 Ų
- H-Brücken-Donoren
- 6
- H-Brücken-Akzeptoren
- 8
- Frei drehbare Bindungen
- 6
- Schwere Atome
- 29
- Formalladung
- 0
- Komplexität
- 202
Experimentelle und physikochemische Eigenschaften
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheit und Regulatorisches
GHS-Klassifizierung
GHS Classification
Danger
H301 (71.4%): Toxic if swallowed [Danger Acute toxicity, oral]
P261, P264, P270, P272, P280, P301+P316, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 147 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Regulatory Information
Regulation (EC) No 178/2002 (amended)
Status: Active Update: 17-07-2015 https://echa.europa.eu/registration-dossier/-/registered-dossier/11520
Health Hazards
SYMPTOMS: Symptoms of exposure to this compound may include nervousness, headache, sweating, nausea and vomiting. Contact dermatitis may occur. Other symptoms include an increase in pulse rate and an increase in blood pressure. Exposure may cause irritation of the skin, eyes and respiratory tract, central nervous system effects, peripheral nervous system effects, loss of appetite, tremors and, in severe cases, convulsions, coma and death. Sleeplessness, restlessness and urinary retention may occur. This compound may cause excitation, insomnia, palpitation, tachycardia, precordial pain, cardiac arrhythmias, vertigo, dryness of the nose and throat, warmth, vesical sphincter spasm and urinary hesitation. It may also cause anxiety, extrasystoles, confusion and delirium. Other symptoms include chills, cyanosis, irritability, fever, suicidal behavior, mania, dilated pupils, blurred vision, opisthotonos, spasms, pulmonary edema, gasping respiration, respiratory failure and anuria. Exposure can lead to giddiness, thirst, difficulty in micturition, muscular weakness, hypertension and ventricular arrhythmias. Overexposure can cause paranoid psychoses, delusions and hallucinations. Mydriasis may occur.
Sicherheit und Schutzausrüstung
First Aid
EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
Nonfire Spill Response
SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.
Personal Protective Equipment (PPE)
RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)
Toxikologische Informationen
Carcinogen Classification
Ephedrine Sulfate
TR-307: Toxicology and Carcinogenesis Studies of Ephedrine Sulfate (CASRN 134-72-5) in F344/N Rats and B6C3F1 Mice (Feed Studies) (1986 )
08/14/85
No Evidence
No Evidence
No Evidence
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Ephedrine sulfate
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
EPHEDRINE SULFATE
beta-Adrenergic Agonist [EPC]; alpha-Adrenergic Agonist [EPC]; Adrenergic alpha-Agonists [MoA]; Increased Norepinephrine Activity [PE]; Adrenergic beta-Agonists [MoA]; Norepinephrine Releasing Agent [EPC]
MeSH Pharmacological Classification
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
Drugs used to cause constriction of the blood vessels.
Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.
Verwendung und Herstellung
Zugehörige Reaktionen
Notizen zur Verbindung
Wird geladen…